‘Nature Communications’ published a fundamental scientific publication on the proprietary technology Urelix™ from UREkA Sarl (“Ureka”), ImmuPharma’s subsidiary.
Findings with the P140 peptide support a direct cross-talk between autophagy and certain central and peripheral neuronal diseases
Cancer compound IPP-204106 chosen to be on the cover of AACR disclosing the specific binding to nucleolin and therefore to tumour cells by the Nucants.
Special article “Resetting the autoreactive immune system with a therapeutic peptide in lupus” on autophagy
New Opportunities for Therapy of Autoimmune Diseases: published in Genetics & Epigenetics outlinung the potential in other indications
Publication of Lupuzor’s double blind phase IIb results in the Annals of the Rheumatic Diseases of the British Medical Journal
Publication in the Journal of Autoimmunity on Peptide-based approaches to treat lupus and other autoimmune diseases
Annals of the Rheumatic Diseases paper on mode of action of Lupuzor on HSC70+ antigen-presenting cells